Should Patients with Atrial Fibrillation and 1 Stroke Risk Factor (CHA2DS2-VASc Score 1 in Men, 2 in Women) Be Anticoagulated?: The CHA2 DS2-VASc 1 Conundrum: Decision Making at the Lower End of the Risk Spectrum

Circulation

Volumn 133, Issue 15, 2016, Pages 1504-1511

  Savino, John A ^a   Halperin, Jonathan L ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT;

AGE; AGED; ATRIAL FIBRILLATION; CARDIOLOGY; CHEMICALLY INDUCED; CLASSIFICATION; COMORBIDITY; COMPLICATION; DECISION MAKING; ETHNOLOGY; EUROPE; FEMALE; HEMORRHAGE; HUMAN; MALE; MEDICAL SOCIETY; PRACTICE GUIDELINE; RISK ASSESSMENT; RISK FACTOR; SEVERITY OF ILLNESS INDEX; SEX DIFFERENCE; STROKE; TAIWAN; THROMBOPHILIA; UNITED STATES;

AGE FACTORS; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; CARDIOLOGY; COMORBIDITY; DECISION MAKING; EUROPE; FEMALE; HEMORRHAGE; HUMANS; MALE; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SOCIETIES, MEDICAL; STROKE; TAIWAN; THROMBOPHILIA; UNITED STATES;

EID: 84964455515     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.115.016715     Document Type: Article

References (48)

1. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW, American College of Cardiology/American Heart Association Task Force on Practice Guidelines 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014 64 e1 e76. doi: 10.1016/j.jacc.2014.03.022
2. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P, ESC Committee for Practice Guidelines-CPG; Document Reviewers 2012 Focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation: developed with the special contribution of the European Heart Rhythm Association. Europace 2012 14 1385 1413. doi: 10.1093/europace/eus305
3. World Health Organization The 10 Leading Causes of Death in the World, 2000 and 2012. May 2014. http://www.who.int/mediacentre/factsheets/fs310/en/. Accessed May 12, 2015
4. Atrial Fibrillation Investigators Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994 154 1449 1457
5. Stroke Prevention in Atrial Fibrillation Investigators. Risk factors for thromboembolism during aspirin therapy in patients with atrial fibrillation: the Stroke Prevention in Atrial Fibrillation Study. J Stroke Cerebrovasc Dis 1995 5 147 157
6. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ, Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001 285 2864 2870
7. Desk R, Williams L, Health K, Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation. Stroke 2008 39 1901 1910
8. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ, Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest 2010 137 263 272. doi: 10.1378/chest.09-1584
9. Piccini JP, Stevens SR, Chang Y, Singer DE, Lokhnygina Y, Go AS, Patel MR, Mahaffey KW, Halperin JL, Breithardt G, Hankey GJ, Hacke W, Becker RC, Nessel CC, Fox KA, Califf RM, ROCKET AF Steering Committee and Investigators Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation 2013 127 224 232. doi: 10.1161/CIRCULATIONAHA.112.107128
10. Singer DE, Chang Y, Borowsky LH, Fang MC, Pomernacki NK, Udaltsova N, Reynolds K, Go AS, A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. J Am Heart Assoc 2013 2 e000250. doi: 10.1161/JAHA.113.000250
11. Chao TF, Liu CJ, Wang KL, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Chen TJ, Lip GY, Chen SA, Using the CHA2DS2-VASc score for refining stroke risk stratification in "low-risk" Asian patients with atrial fibrillation. J Am Coll Cardiol 2014 64 1658 1665. doi: 10.1016/j.jacc.2014.06.1203
12. DeLong ER, DeLong DM, Clarke-Pearson DL, Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988 44 837 845
13. Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW, Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials: the Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Stroke 1999 30 1223 1229
14. Singer DE, Chang Y, Fang MC, Borowsky LH, Pomernacki NK, Udaltsova N, Go AS, The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009 151 297 305
15. Chao TF, Liu CJ, Wang KL, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Chen TJ, Lip GY, Chen SA, Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation? J Am Coll Cardiol 2015 65 635 642. doi: 10.1016/j.jacc.2014.11.046
16. Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, Selmer C, Ahlehoff O, Olsen AM, Gislason GH, Torp-Pedersen C, Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 2011 342 d124
17. Wang JG, Staessen JA, Franklin SS, Fagard R, Gueyffier F, Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome. Hypertension 2005 45 907 913. doi: 10.1161/01.HYP.0000165020.14745.79
18. Lip GY, Frison L, Grind M, SPORTIF Investigators Effect of hypertension on anticoagulated patients with atrial fibrillation. Eur Heart J 2007 28 752 759. doi: 10.1093/eurheartj/ehl504
19. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ, Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001 285 2864 2870
20. Atrial Fibrillation Investigators Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1066 patients from 3 clinical trials. Arch Intern Med 1998 17 357 364
21. Friberg L, Skeppholm M, Terént A, Benefit of anticoagulation unlikely in patients with atrial fibrillation and a CHA2DS2-VASc score of 1. J Am Coll Cardiol 2015 65 225 232. doi: 10.1016/j.jacc.2014.10.052
22. Lip GY, Skjøth F, Rasmussen LH, Larsen TB, Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score. J Am Coll Cardiol 2015 65 1385 1394. doi: 10.1016/j.jacc.2015.01.044
23. Chao TF, Wang KL, Liu CJ, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Chung FP, Liao JN, Chen TJ, Chiang CE, Lip GY, Chen SA, Age threshold for increased stroke risk among patients with atrial fibrillation: a nationwide cohort study from Taiwan. J Am Coll Cardiol 2015 66 1339 1347. doi: 10.1016/j.jacc.2015.07.026
24. Tsai CF, Thomas B, Sudlow CL, Epidemiology of stroke and its subtypes in Chinese vs white populations: a systematic review. Neurology 2013 81 264 272. doi: 10.1212/WNL.0b013e31829bfde3
25. Gunarathne A, Patel JV, Gammon B, Gill PS, Hughes EA, Lip GY, Ischemic stroke in South Asians: a review of the epidemiology, pathophysiology, and ethnicity-related clinical features. Stroke 2009 40 e415 e423. doi: 10.1161/STROKEAHA.108.535724
26. Hijazi Z, Oldgren J, Andersson U, Connolly SJ, Ezekowitz MD, Hohnloser SH, Reilly PA, Vinereanu D, Siegbahn A, Yusuf S, Wallentin L, Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy. Circulation 2012 125 1605 1616. doi: 10.1161/CIRCULATIONAHA.111.038729
27. Omland T, de Lemos JA, Sabatine MS, Christophi CA, Rice MM, Jablonski KA, Tjora S, Domanski MJ, Gersh BJ, Rouleau JL, Pfeffer MA, Braunwald E, Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) Trial Investigators A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med 2009 361 2538 2547. doi: 10.1056/NEJMoa0805299
28. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr, Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 2002 40 976 982
29. Inoue S, Murakami Y, Sano K, Katoh H, Shimada T, Atrium as a source of brain natriuretic polypeptide in patients with atrial fibrillation. J Card Fail 2000 6 92 96
30. Patton KK, Ellinor PT, Heckbert SR, Christenson RH, DeFilippi C, Gottdiener JS, Kronmal RA, N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: the Cardiovascular Health Study. Circulation 2009 120 1768 1774. doi: 10.1161/CIRCULATIONAHA.109.873265
31. Yamada T, Murakami Y, Okada T, Okamoto M, Shimizu T, Toyama J, Yoshida Y, Tsuboi N, Ito T, Muto M, Kondo T, Inden Y, Hirai M, Murohara T, Plasma atrial natriuretic peptide and brain natriuretic peptide levels after radiofrequency catheter ablation of atrial fibrillation. Am J Cardiol 2006 97 1741 1744. doi: 10.1016/j.amjcard.2005.12.071
32. Hijazi Z, Wallentin L, Siegbahn A, Andersson U, Christersson C, Ezekowitz J, Gersh BJ, Hanna M, Hohnloser S, Horowitz J, Huber K, Hylek EM, Lopes RD, McMurray JJ, Granger CB, N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). J Am Coll Cardiol 2013 61 2274 2284. doi: 10.1016/j.jacc.2012.11.082
33. Agmon Y, Khandheria BK, Gentile F, Seward JB, Echocardiographic assessment of the left atrial appendage. J Am Coll Cardiol 1999 34 1867 1877
34. Kamp O, Verhorst PM, Welling RC, Visser CA, Importance of left atrial appendage flow as a predictor of thromboembolic events in patients with atrial fibrillation. Eur Heart J 1999 20 979 985. doi: 10.1053/euhj.1998.1453
35. Antonielli E, Pizzuti A, Pálinkás A, Tanga M, Gruber N, Michelassi C, Varga A, Bonzano A, Gandolfo N, Halmai L, Bassignana A, Imran MB, Delnevo F, Csanády M, Picano E, Clinical value of left atrial appendage flow for prediction of long-term sinus rhythm maintenance in patients with nonvalvular atrial fibrillation. J Am Coll Cardiol 2002 39 1443 1449
36. Korhonen M, Muuronen A, Arponen O, Mustonen P, Hedman M, Jäkälä P, Vanninen R, Taina M, Left atrial appendage morphology in patients with suspected cardiogenic stroke without known atrial fibrillation. PLOS One 2015 10 e0118822. doi: 10.1371/journal.pone.0118822
37. Di Biase L, Santangeli P, Anselmino M, Mohanty P, Salvetti I, Gili S, Horton R, Sanchez JE, Bai R, Mohanty S, Pump A, Cereceda Brantes M, Gallinghouse GJ, Burkhardt JD, Cesarani F, Scaglione M, Natale A, Gaita F, Does the left atrial appendage morphology correlate with the risk of stroke in patients with atrial fibrillation? Results from a multicenter study. J Am Coll Cardiol 2012 60 531 538. doi: 10.1016/j.jacc.2012.04.032
38. Azemi T, Rabdiya VM, Ayirala SR, McCullough LD, Silverman DI, Left atrial strain is reduced in patients with atrial fibrillation, stroke or TIA, and low risk CHADS(2) scores. J Am Soc Echocardiogr 2012 25 1327 1332. doi: 10.1016/j.echo.2012.09.004
39. Daccarett M, Badger TJ, Akoum N, Burgon NS, Mahnkopf C, Vergara G, Kholmovski E, McGann CJ, Parker D, Brachmann J, Macleod RS, Marrouche NF, Association of left atrial fibrosis detected by delayed-enhancement magnetic resonance imaging and the risk of stroke in patients with atrial fibrillation. J Am Coll Cardiol 2011 57 831 838. doi: 10.1016/j.jacc.2010.09.049
40. Steinberg BA, Hellkamp AS, Lokhnygina Y, Patel MR, Breithardt G, Hankey GJ, Becker RC, Singer DE, Halperin JL, Hacke W, Nessel CC, Berkowitz SD, Mahaffey KW, Fox KA, Califf RM, Piccini JP, ROCKET-AF Steering Committee and Investigators Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. Eur Heart J 2015 36 288 296. doi: 10.1093/eurheartj/ehu359
41. Jahangir A, Lee V, Friedman PA, Trusty JM, Hodge DO, Kopecky SL, Packer DL, Hammill SC, Shen WK, Gersh BJ, Long-term progression and outcomes with aging in patients with lone atrial fibrillation: a 30-year follow-up study. Circulation 2007 115 3050 3056. doi: 10.1161/CIRCULATIONAHA.106.644484
42. Rosand J, Eckman MH, Knudsen KA, Singer DE, Greenberg SM, The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med 2004 164 880 884. doi: 10.1001/archinte.164.8.880
43. Singer DE, Chang Y, Fang MC, Borowsky LH, Pomernacki NK, Udaltsova N, Go AS, The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009 151 297 305
44. Fang MC, Go AS, Chang Y, Hylek EM, Henault LE, Jensvold NG, Singer DE, Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med 2007 120 700 705. doi: 10.1016/j.amjmed.2006.07.034
45. Lip GY, Andreotti F, Fauchier L, Huber K, Hylek E, Knight E, Lane D, Levi M, Marín F, Palareti G, Kirchhof P, European Heart Rhythm Association Bleeding risk assessment and management in atrial fibrillation patients: executive summary of a position document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. Thromb Haemost 2011 106 997 1011. doi: 10.1160/TH11-10-0690
46. Eckman MH, Singer DE, Rosand J, Greenberg SM, Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 2011 4 14 21. doi: 10.1161/CIRCOUTCOMES.110.958108
47. Chatterjee S, Sardar P, Biondi-Zoccai G, Kumbhani DJ, New oral anticoagulants and the risk of intracranial hemorrhage: traditional and bayesian meta-analysis and mixed treatment comparison of randomized trials of new oral anticoagulants in atrial fibrillation. JAMA Neurol 2013 70 1486 1490. doi: 10.1001/jamaneurol.2013.4021
48. Lauer A, Pfeilschifter W, Schaffer CB, Lo EH, Foerch C, Intracerebral haemorrhage associated with antithrombotic treatment: translational insights from experimental studies. Lancet Neurol 2013 12 394 405. doi: 10.1016/S1474-4422(13)70049-8